SARS-CoV-2 Lysate Stimulation Impairs the Release of Platelet-like Particles and Megakaryopoiesis in the MEG-01 Cell Line

Int J Mol Sci. 2023 Mar 1;24(5):4723. doi: 10.3390/ijms24054723.

Abstract

SARS-CoV-2 infection causes a considerable inflammatory response coupled with impaired platelet reactivity, which can lead to platelet disorders recognized as negative prognostic factors in COVID-19 patients. The virus may cause thrombocytopenia or thrombocytosis during the different disease stages by destroying or activating platelets and influencing platelet production. While it is known that several viruses can impair megakaryopoiesis by generating an improper production and activation of platelets, the potential involvement of SARS-CoV-2 in affecting megakaryopoiesis is poorly understood. To this purpose, we explored, in vitro, the impact of SARS-CoV-2 stimulation in the MEG-01 cell line, a human megakaryoblastic leukemia cell line, considering its spontaneous capacity of releasing platelet-like particles (PLPs). We interrogated the effect of heat-inactivated SARS-CoV-2 lysate in the release of PLPs and activation from MEG-01, the signaling pathway influenced by SARS-CoV-2, and the functional effect on macrophagic skewing. The results highlight the potential influence of SARS-CoV-2 in the early stages of megakaryopoiesis by enhancing the production and activation of platelets, very likely due to the impairment of STATs signaling and AMPK activity. Overall, these findings provide new insight into the role of SARS-CoV-2 in affecting megakaryocyte-platelet compartment, possibly unlocking another avenue by which SARS-CoV-2 moves.

Keywords: MEG-01; SARS-CoV-2; megakaryopoiesis; platelets.

MeSH terms

  • Blood Platelets* / metabolism
  • COVID-19* / metabolism
  • Cell Line
  • Humans
  • Megakaryocytes / metabolism
  • SARS-CoV-2

Grants and funding

This work was supported by: Fondo di ateneo per la ricerca di base, ORSA229281 to E.C. and A.A.P.; research funding from PRIN 2020YRETTX_001 to A.A.P.; Cariplo Foundation (n.2016-0874) to A.A.P.; Ministry of Health (RF-2016-02364864) to A.A.P.